Janux Therapeutics
Most recent annual filing: 2026-02-26
- JANX011 Ph1 interim2H 2026JANX011 Ph1 interim, 2H 2026, material
- JANX013 trial start2H 2026JANX013 trial start, 2H 2026, routine
- JANX007 readout1H 2027JANX007 readout, 1H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
JANX011
- Undisclosed indication
JANX013
Technology platforms
TRACTr
Tumor Activated T Cell Engager platform — bispecific molecules with tumor antigen-binding domain and CD3 T cell binding domain, with tumor-protease-cleavable peptide masks and albumin-binding domain for extended half-life; focus on solid tumors in oncology
Targets: CD3, PSMA
TRACIr
Tumor Activated Immunomodulator platform — bispecific molecules with tumor antigen-binding domain and costimulatory CD28 binding domain; designed to enhance T cell activation and durability; focus on solid tumors in oncology
Targets: CD28, PSMA
ARM
Adaptive Immune Response Modulator platform — redesigned bispecific T cell engagers targeting B cells via CD19 for rapid, deep and durable B-cell depletion with memory B-cell reset; off-the-shelf, subcutaneous, re-dosable format; focus on autoimmune diseases and oncology
Targets: CD19, CD3
TRACTr · Bristol Myers Squibb
Tumor Activated T Cell Engager platform; focus areas include prostate cancer and other solid tumors
Targets: PSMA
TRACTr · Merck
Tumor Activated T Cell Engager platform — proprietary immunotherapy technology producing novel T cell engager candidates for cancer treatment
Discontinued (1)
- JANX008 — undisclosed · strategic deprioritization following completion of Phase 1a
Biotech Distilled coverage (4)
- 2026-08-07 UPDATE: Janux Therapeutics (JANX) - The Quiet Quarter With a Loud R&D Line 🔒 Paid
- 2026-06-23 UPDATE: Janux Therapeutics (JANX) - The CMO Walks After Six Months 🔒 Paid
- 2026-05-09 UPDATE: Janux Therapeutics (JANX) - The BMS Milestone Hits, the Catalyst Slips 🔒 Paid
- 2026-04-29 Janux Pharmaceuticals (JANX) - Scientific Deep Dive for JANX007 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.